Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

    NEXT STORY
    Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma
    PREV STORY
    Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Shrimp Disease Diagnostics Market Anticipated to Reach at a CAGR 6.5% during 2019-2029 – PMR

    author_avatar
    NASDAQ Market News

    Teleflex Convenes Urologists in Australia for Summit on Treating Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms

    author_avatar
    NASDAQ Market News

    BrainsWay’s Deep TMS Takes Center Stage at Clinical TMS Society Annual Poster Session

    author_avatar
    NASDAQ Market News